Investment Risk Analysis: MODEPHARMA LIMITED

1. Risk Rating: MEDIUM

Justification: While the company demonstrates adequate solvency with positive net assets of £199,264 and a comfortable liquidity position, the significant volatility in net assets over recent years and a notable 25.8% year-over-year decline in shareholders' funds raises concerns about operational stability and earnings predictability. The micro-entity filing status further limits visibility into the underlying causes of these fluctuations.

2. Key Concerns

Concern 1: Significant Volatility in Net Assets

The company's net assets have exhibited substantial swings over the five-year period: £367,782 (2021) → £313,314 (2022) → £131,748 (2023) → £268,713 (2024) → £199,264 (2025). This pattern suggests unpredictable business performance, potential reliance on one-off items, or possible asset revaluations. The 56% decline from 2022 to 2023 followed by a 104% recovery in 2024, then a further 26% decline in 2025, is atypical for a stable business support services company and warrants explanation.

Concern 2: Declining Current Assets Trajectory

Current assets fell from £332,662 (2024) to £227,056 (2025)—a reduction of approximately £105,600 or 31.7%. Without a profit and loss account or cash flow statement (permitted under micro-entity reporting), it is impossible to determine whether this reflects cash depletion, debtor write-offs, or a deliberate reduction in trade debtors. The composition and quality of these current assets cannot be assessed from available filings.

Concern 3: Minimal Disclosure and Audit Exemption

As a micro-entity, the company files abbreviated accounts with no requirement for a profit and loss account, cash flow statement, or directors' report. The accounts are unaudited. This significantly restricts an investor's ability to assess trading performance, margin trends, cash generation, and related party transactions. The £100 share capital also provides negligible capital cushion relative to the asset base, suggesting the business is funded primarily through retained profits and potentially director loans.

3. Positive Indicators

Positive 1: Strong Liquidity Position

The current ratio stands at approximately 7.1:1 (£227,056 / £32,014), indicating a substantial buffer to meet short-term obligations. Net current assets of £195,042 provide considerable headroom, and the company carries minimal long-term debt (£1,747).

Positive 2: Positive Net Assets and No Indications of Financial Distress

The company maintains positive shareholders' funds of £199,264 with total liabilities of only £32,014 against total assets of £233,025. There are no indications of insolvency, county court judgments, or overdue filings. Both current and long-term liabilities have been reduced year-over-year.

Positive 3: Regulatory Compliance and Longevity

The company has been actively trading for over 17 years since incorporation in 2007. All statutory filings (accounts and confirmation statements) are current and not overdue. The company appears to be well-maintained from a compliance perspective.

4. Due Diligence Notes

Item 1: Composition of Current Assets

Request a breakdown of the £227,056 in current assets—specifically the split between cash at bank, trade debtors, and other debtors. The significant year-over-year decline may indicate cash extraction, debtor collection issues, or a change in business activity. Understanding whether these assets are readily realisable is critical.

Item 2: Profit and Loss Performance

Obtain management accounts or detailed P&L information to understand the trading performance underlying the net asset movements. The micro-entity accounts provide no visibility on turnover, cost of sales, or operating profit. The volatility in net assets suggests either significant trading losses/gains or substantial dividend/withdrawal activity that should be quantified.

Item 3: Related Party Transactions and Director Loans

Investigate whether the two PSCs (Mr. Oliver Gupta and Ms. Rima Uppal, who together control 50-100% of the company) have made loans to or from the company. The fluctuations in net assets could reflect movements in director loan accounts. Micro-entity accounts are not required to disclose related party transactions, creating a significant blind spot.

Item 4: Business Activity and Name Change

The company traded as "MODE BPO LIMITED" until March 2015, suggesting a previous focus on Business Process Outsourcing. The current SIC code (82990—other business support service activities) and the "Modepharma" branding suggest a pivot toward pharmaceutical-related services. Clarify the nature of the current business model, client concentration, and whether the name change reflected a fundamental shift in operations that may explain the financial volatility.

Item 5: Long-term Creditor Reduction

Long-term creditors decreased from £11,747 to £1,747—a reduction of £10,000. Determine whether this represents scheduled repayment of a loan, director loan repayment, or settlement of another obligation. Understanding the nature of this liability and its terms would inform whether the company has been servicing debt appropriately.